Lipigon Pharmaceuticals AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was SEK 0.148 million compared to SEK 0.037 million a year ago. Net loss was SEK 7.56 million compared to SEK 9.2 million a year ago. Basic loss per share from continuing operations was SEK 0.09 compared to SEK 0.45 a year ago. Diluted loss per share from continuing operations was SEK 0.05 compared to SEK 0.44 a year ago.
For the full year, sales was SEK 16.41 million. Revenue was SEK 17.48 million compared to SEK 0.39 million a year ago. Net loss was SEK 12.13 million compared to SEK 37.71 million a year ago. Basic loss per share from continuing operations was SEK 0.19 compared to SEK 2.57 a year ago. Diluted loss per share from continuing operations was SEK 0.19 compared to SEK 2.57 a year ago.